H B Carter
Affiliation: Johns Hopkins University
- Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancerH B Carter
Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
JAMA 277:1456-60. 1997..To evaluate prostate-specific antigen (PSA) testing intervals that maintain the detection of curable cancer and reduce unnecessary testing...
- Prostate-specific antigen testing of older menH B Carter
Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
J Natl Cancer Inst 91:1733-7. 1999....
- Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancerS M Harman
The Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
J Clin Endocrinol Metab 85:4258-65. 2000..Our data suggest that IGF-II may inhibit both prostate growth and development of prostate cancer...
- Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of AgingJ Fang
National Institute on Aging, Gerontology Research Center, Baltimore, Maryland, USA
Urology 58:411-6. 2001..Those men with the lowest risk of prostate cancer on the basis of the baseline PSA measurements are unlikely to benefit from frequent PSA surveillance in an effort to detect prostate cancer early...
- Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostateH B Carter
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
World J Urol 15:359-63. 1997..This information is useful when counseling men regarding management options for non-palpable, PSA detected prostate cancer...
- Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c diseaseJ I Epstein
Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
J Urol 166:1688-91. 2001..Furthermore, men undergoing watchful waiting can be reassured that there is little evidence that prostate cancer grade worsens during the short term...
- Plasma selenium level before diagnosis and the risk of prostate cancer developmentJ D Brooks
Department of Urology, Stanford University Medical Center, Stanford, California, USA
J Urol 166:2034-8. 2001..These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer. Because plasma selenium decreases with patient age, supplementation may be particularly beneficial to older men...
- Importance of posterolateral needle biopsies in the detection of prostate cancerJ I Epstein
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Urology 57:1112-6. 2001..Maximum cancer detection results from combining both routine sextant and posterolateral needle biopsies...
- Effect of local anesthetics on patient recovery after transrectal biopsyC L Wu
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA
Urology 57:925-9. 2001..CONCLUSIONS: Injection of lidocaine lateral to the seminal vesicles before prostate biopsy did not diminish biopsy-associated pain...
- The role of prostate-specific antigen velocity in prostate cancer early detectionS R Potter
Department of Urology, The Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
Curr Urol Rep 1:15-9. 2000..This review briefly summarizes the theoretic basis and clinical utility of PSAV in prostate cancer early detection...
- Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignanciesW G Nelson
Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
Cancer Chemother Pharmacol 46:S67-72. 2000....